Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
This study will test whether addition of imiquimod to standard antimony therapy provides a
significant benefit in subjects with newly diagnosed cutaneous leishmaniasis. Based on our
previous results, we hypothesize that lesions in patients who receive the combined treatment
of pentavalent antimony and imiquimod as a first line therapy will resolve more rapidly and
produce less scarring than treatment with pentavalent antimony alone.